TY - JOUR
T1 - Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications
AU - Banaschewski, T.
AU - Coghill, D.
AU - Santosh, P.
AU - Zuddas, A.
AU - Asherson, P.
AU - Buitelaar, J.
AU - Danckaerts, M.
AU - Döpfner, M.
AU - Faraone, S.V.
AU - Rothenberger, A.
AU - Sergeant, J.A.
AU - Steinhausen, H.C.
AU - Sonuga-Barke, E.J.S.
AU - Taylor, E.
PY - 2008
Y1 - 2008
N2 - A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorders, on the basis of which practical recommendations for the application of these medications have been developed. The current article outlines results of this analysis, comparing the effect sizes and numbers-needed to-treat for extended-release stimulant preparations and atomoxetine (ATX). It is concluded (1) that long-acting preparations should be licensed and used. (2) However, they should not completely replace short-acting medications, in view of costs as well as the greater flexibility of dosing. Individual choices of therapy are necessary. (3) Both ATX and retarded-release stimulants should be available. © 2008 by Verlag Hans Huber, Hogrefe AG.
AB - A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorders, on the basis of which practical recommendations for the application of these medications have been developed. The current article outlines results of this analysis, comparing the effect sizes and numbers-needed to-treat for extended-release stimulant preparations and atomoxetine (ATX). It is concluded (1) that long-acting preparations should be licensed and used. (2) However, they should not completely replace short-acting medications, in view of costs as well as the greater flexibility of dosing. Individual choices of therapy are necessary. (3) Both ATX and retarded-release stimulants should be available. © 2008 by Verlag Hans Huber, Hogrefe AG.
U2 - 10.1024/1422-4917.36.2.97
DO - 10.1024/1422-4917.36.2.97
M3 - Article
VL - 36
SP - 97
EP - 106
JO - Zeitschrift für Kinder und Jugendpsychiatrie und Psychotherapie
JF - Zeitschrift für Kinder und Jugendpsychiatrie und Psychotherapie
SN - 1422-4917
IS - 2
ER -
